|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA: A Cancer Journal for Clinicians. 65:5–29.
2015.PubMed/NCBI
|
|
2
|
Park JC and Eisenberger MA: Advances in
the Treatment of Metastatic Prostate Cancer. Mayo Clin Proc.
90:1719–1733. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 5:871–90. 2009. View Article : Google Scholar
|
|
4
|
Park M, Dean M, Kaul K, Braun MJ, Gonda MA
and Vande WG: Sequence of MET protooncogene cDNA has features
characteristic of the tyrosine kinase family of growth-factor
receptors. Proc Natl Acad Sci U S A. 84:pp. 6379–83. 1987;
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chang K, Karnad A, Zhao S and Freeman JW:
Roles of c-Met and RON kinases in tumor progression and their
potential as therapeutic targets. Oncotarget. 6:3507–18. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ronsin C, Muscatelli F, Mattei MG and
Breathnach R: A novel putative receptor protein tyrosine kinase of
the met family. Oncogene. 8:1195–202. 1993.PubMed/NCBI
|
|
7
|
Birchmeier C, Birchmeier W, Gherardi E and
Woude GF Vande: Met, metastasis, motility and more. Nat Rev Mol
Cell Bio. 4:915–925. 2003. View
Article : Google Scholar
|
|
8
|
Wang J, Rajput A, Kan JLC, Rose R, Liu XQ,
Kuropatwinski K, Hauser J, Beko A, Dominquez I, Sharratt EA,
Brattain L, LeVea C, Sun FL, Keane DM, Gibson NW and Brattain MG:
Knockdown of Ron Kinase Inhibits Mutant Phosphatidylinositol
3-Kinase and Reduces Metastasis in Human Colon Carcinoma. J Biol
Chem. 284:10912–10922. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee WY, Chen HH, Chow NH, Su WC, Lin PW
and Guo HR: Prognostic significance of co-expression of RON and MET
receptors in node-negative breast cancer patients. Clin Cancer Res.
11:2222–8. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Faria CC, Golbourn BJ, Dubuc AM, Remke M,
Diaz RJ, Agnihotri S, Luck A, Sabha N, Olsen S, Wu X, Garzia L,
Ramaswamy V, Mack SC, Wang X, Leadley M, Reynaud D, Ermini L, Post
M, Northcott PA, Pfister SM, Croul SE, Kool M, Korshunov A, Smith
CA, Taylor MD and Rutka JT: Foretinib Is Effective Therapy for
Metastatic Sonic Hedgehog Medulloblastoma. Cancer Res. 75:134–146.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kataoka Y, Mukohara T, Tomioka H,
Funakoshi Y, Kiyota N, Fujiwara Y, Yashiro M, Hirakawa K, Hirai M
and Minami H: Foretinib (GSK1363089), a multi-kinase inhibitor of
MET and VEGFRs, inhibits growth of gastric cancer cell lines by
blocking inter-receptor tyrosine kinase networks. Invest New Drugs.
30:1352–60. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huynh H, Ong R and Soo KC: Foretinib
demonstrates anti-tumor activity and improves overall survival in
preclinical models of hepatocellular carcinoma. Angiogenesis.
15:59–70. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
You WK, Sennino B, Williamson CW, Falcon
B, Hashizume H, Yao LC, Aftab DT and McDonald DM: VEGF and c-Met
blockade amplify angiogenesis inhibition in pancreatic islet
cancer. Cancer Res. 71:4758–68. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huynh H, Ong R and Soo KC: Foretinib
demonstrates anti-tumor activity and improves overall survival in
preclinical models of hepatocellular carcinoma. Angiogenesis.
15:59–70. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shah MA, Wainberg ZA, Catenacci DV,
Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe
DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T
and Bottaro DP: Phase II study evaluating 2 dosing schedules of
oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients
with metastatic gastric cancer. Plos One. 8:e540142013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Choueiri TK, Vaishampayan U, Rosenberg JE,
Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN,
Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas
NB, Flaherty KT, Ross R, Eisenberg P, Meltzer PS, Merino MJ,
Bottaro DP, Linehan WM and Srinivasan R: Phase II and biomarker
study of the dual MET/VEGFR2 inhibitor foretinib in patients with
papillary renal cell carcinoma. J Clin Oncol. 31:181–6. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Seiwert T, Sarantopoulos J, Kallender H,
McCallum S, Keer HN and Blumenschein G: Phase II trial of
single-agent foretinib (GSK1363089) in patients with recurrent or
metastatic squamous cell carcinoma of the head and neck. Invest New
Drug. 2:417–24. 2012.
|
|
18
|
Yau T, Yen CJ, Chen PJ, Chau Y, Lencioni
R, Kallender H, Ottesen LH and Poon RTP: A phase I/II study of
foretinib, an oral multikinase inhibitor targeting MET RON, AXL,
TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC). J
Hepatol. 54:S2682011. View Article : Google Scholar
|
|
19
|
Knubel KH, Pernu BM, Sufit A, Nelson S,
Pierce AM and Keating AK: MerTK inhibition is a novel therapeutic
approach for glioblastoma multiforme. Oncotarget. 5:1338–51. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shtutman M, Levina E, Ohouo P, Baig M and
Roninson IB: Cell Adhesion Molecule L1 Disrupts
E-Cadherin-Containing Adherens Junctions and Increases Scattering
and Motility of MCF7 Breast Carcinoma Cells. Cancer Res.
66:11370–11380. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yao H, Zhou Y, Zhang R and Wang M: MSP-RON
signalling in cancer: pathogenesis and therapeutic potential. Nat
Rev Cancer. 13:466–481. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kretschmann KL, Eyob H, Buys SS and Welm
AL: The macrophage stimulating protein/Ron pathway as a potential
therapeutic target to impede multiple mechanisms involved in breast
cancer progression. Curr Drug Targets. 11:1157–68. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee WY, Chen HH, Chow NH, Su WC, Lin PW
and Guo HR: Prognostic significance of co-expression of RON and MET
receptors in node-negative breast cancer patients. Clin Cancer Res.
11:2222–8. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Follenzi A, Bakovic S, Gual P, Stella MC,
Longati P and Comoglio PM: Cross-talk between the proto-oncogenes
Met and Ron. Oncogene. 19:3041–9. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Benvenuti S, Lazzari L, Arnesano A, Li CG,
Gentile A and Comoglio PM: Ron kinase transphosphorylation sustains
MET oncogene addiction. Cancer Res. 71:1945–55. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang D, Shen Q, Chen YQ and Wang MH:
Collaborative activities of macrophage-stimulating protein and
transforming growth factor-beta1 in induction of epithelial to
mesenchymal transition: roles of the RON receptor tyrosine kinase.
Oncogene. 23:1668–80. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ma Q, Guin S, Padhye SS, Zhou YQ, Zhang RW
and Wang MH: Ribosomal protein S6 kinase (RSK)-2 as a central
effector molecule in RON receptor tyrosine kinase mediated
epithelial to mesenchymal transition induced by
macrophage-stimulating protein. Mol Cancer. 10:662011. View Article : Google Scholar : PubMed/NCBI
|
